Vanguard Group’s InspireMD NSPR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2019
Q2 | – | Sell |
-58
| Closed | -$6K | – | 4180 |
|
|
2019
Q1 | $6K | Hold |
58
| – | – | ﹤0.01% | 4117 |
|
|
2018
Q4 | $7K | Hold |
58
| – | – | ﹤0.01% | 4148 |
|
|
2018
Q3 | $10K | Hold |
58
| – | – | ﹤0.01% | 4162 |
|
|
2018
Q2 | $11K | Buy |
58
+36
| +164% | +$30.6K | ﹤0.01% | 4125 |
|
|
2018
Q1 | $17K | Buy |
+22
| New | +$75.8K | ﹤0.01% | 4093 |
|
|
2017
Q2 | – | Sell |
-1
| Closed | -$19K | – | 4077 |
|
|
2017
Q1 | $19K | Hold |
1
| – | – | ﹤0.01% | 4059 |
|
|
2016
Q4 | $41K | Buy |
+1
| New | +$65.7K | ﹤0.01% | 4045 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 4076 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 4122 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 4112 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 4139 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 4124 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 4119 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 4115 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3971 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 3830 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3862 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3832 |
|
Other funds holding NSPR
Vanguard Group's NSPR Position: Q2 2019 in Review
Vanguard Group sold out of InspireMD (NSPR) in Q2 2019, closing a stake of 58 shares — an estimated $6K sold.
Vanguard Group first reported a position in NSPR in Q4 2016 and held it in 7 quarters. The position peaked at $41K in Q4 2016. 3 funds tracked by Wall St. Rank hold NSPR as of Q2 2019.
- Vanguard Group reported no remaining InspireMD position as of Q2 2019 after selling out during the quarter.
- Vanguard Group sold 58 InspireMD shares in Q2 2019, an estimated $6K.
- Vanguard Group first reported a position in InspireMD in Q4 2016 and held it in 7 quarters.
- Vanguard Group's InspireMD position peaked at $41K in Q4 2016.
- 3 funds tracked by Wall St. Rank held InspireMD as of Q2 2019.
Based on Vanguard Group's 13F filing for Q2 2019, filed 14 Aug 2019.